Successfully Integrate Minimal Residual Disease (MRD) Assessment in Clinical Trials to Enable Earlier Treatment Interventions & More Accurate Dosing Regimens, Thereby Enhancing Precision Therapies & Improving Patient Outcomes
Welcome to the 3rd Liquid Biopsy Surveillance Summit
Liquid biopsies are revolutionizing clinical trials, emerging as a game-changing diagnostic tool for monitoring molecular residual disease and detecting disease resistance. This breakthrough enables precise patient stratification, ensuring they receive the most effective and safe treatments. In 2024, a wave of collaborations has surged, propelling the use of liquid biopsies for MRD testing to new heights. The FDA's recognition of MRD as an endpoint in multiple myeloma marks a monumental leap forward for the field, heralding a new era in patient care and therapeutic development.
The 3rd Liquid Biopsy Surveillance Summit returns as the leading East Coast forum solely dedicated to MRD detection in clinical trials to improve stage response monitoring to get patients earlier access to precision treatments.
Expect to hear critical insights from leading biopharma, oncologists and diagnostic providers to utilise liquid biopsies as surrogate endpoints in clinical trials, guide dosing decisions and enable the development of precise drugs for patients with unmet needs in oncology and beyond.
Join your peers from Biomarker, Translational and Clinical Development teams to more accurately monitor drug response through MRD assessments for improved treatment regimens from early to late stage clinical trials to improve patient outcomes.
World-Class Speaker Faculty Includes:
Gabriele Allegri
Vice President - Global Commercial Precision Medicine
Johnson & Johnson Innovative Medicine
Jean-Francois Martini
Executive Director - Translational Oncology Lead, Global Product Development - Oncology
Pfizer
Hear What Previous Attendees Have to Say…
“Liquid Biopsies are transforming detection and treatment of many cancers. I look forward to sharing our experiences in MRD in hematologic conditions.”
Speaker, Director - Translational Science, Cancer, Foundation for the NIH
“I have found the meetings to be invaluable for networking with drug development colleagues and diagnostic partners. I always learn something new, and these meetings have significantly influenced the biomarker strategies I have implemented”
Speaker, Associate Director Translational Medicine, Repare Therapeutics
“The event offered a great opportunity to network and promote my company and its services to advance the study in cancer treatment”
Previous Event Partner, Translational Medicine Scientist, Burning Rock Biotech
“It was a great meeting. The topics presented were UpToDate with some information were new. Glad that equity, diversity and inclusion was one of the topics for panel discussion.”
Past Attendee, Associate Director – Precision Medicine, Takeda
“I really enjoyed the mix of speakers and topics - it was nice to see a variety of LBx applications (ctDNA, exosomes, CTCs) and hear from both industry and institutions.”
Past Attendee, Director, AstraZeneca
Our Partners:
Other Events in the Series
